Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00254735|
Recruitment Status : Completed
First Posted : November 17, 2005
Last Update Posted : December 18, 2007
|Condition or disease||Intervention/treatment||Phase|
|Obsessive Compulsive Disorder||Drug: quetiapine fumarate Drug: SSRI/Clomipramine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study|
|Study Start Date :||April 2002|
|Actual Study Completion Date :||March 2006|
- Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.
- Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.
- Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00254735
|Study Director:||AstraZeneca Germany Medical Director, MD||AstraZeneca|